New Delhi: There is good news for clinicians and doctors struggling to save patients from infections by deadly bacteria—the soft launch of nafithromycin, India’s first indigenously developed ...

Nafithromycin’s efficacy stands out as it targets both typical and atypical pathogens, offering a potent solution where no new antibiotic in this class has been developed worldwide for over ...

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults ...

Shares of Wockhardt are higher by 5% on January 3 after Indian drug regulator approved oral antibiotic for the treatment of Pneumonia, the company informed in an exchange filing. Central Drugs ...